Your browser doesn't support javascript.
loading
A novel prognostic nomogram for adult acute lymphoblastic leukemia: a comprehensive analysis of 321 patients.
Zhang, Qian; Huang, Mei-Juan; Wang, Han-Yu; Wu, Yong; Chen, Yuan-Zhong.
Affiliation
  • Zhang Q; Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Huang MJ; Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Wang HY; Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Wu Y; Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
  • Chen YZ; Department of Cardiac Surgery, Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Ann Hematol ; 102(7): 1825-1835, 2023 Jul.
Article in En | MEDLINE | ID: mdl-37173535
ABSTRACT
The cure rate of acute lymphoblastic leukemia (ALL) in adolescents and adults remains poor. This study aimed to establish a prognostic model for ≥14-year-old patients with ALL to guide treatment decisions. We retrospectively analyzed the data of 321 ALL patients between January 2017 and June 2020. Patients were randomly (21 ratio) divided into either the training or validation set. A nomogram was used to construct a prognostic model. Multivariate Cox analysis of the training set showed that age > 50 years, white blood cell count > 28.52×109/L, and MLL rearrangement were independent risk factors for overall survival (OS), while platelet count >37×109/L was an independent protective factor. The nomogram was established according to these independent prognostic factors in the training set, where patients were grouped into two categories low-risk (≤13.15) and high-risk (>13.15). The survival analysis, for either total patients or sub-group patients, showed that both OS and progression-free survival (PFS) of low-risk patients was significantly better than that of high-risk patients. Moreover, treatment analysis showed that both OS and progression-free survival (PFS) of ALL with stem cell transplantation (SCT) were significantly better than that of ALL without SCT. Further stratified analysis showed that in low-risk patients, the OS and PFS of patients with SCT were significantly better than those of patients without SCT. In contrast, in high-risk patients, compared with non-SCT patients, receiving SCT can only significantly prolong the PFS, but it does not benefit the OS. We established a simple and effective prognostic model for ≥ 14-year-old patients with ALL that can provide accurate risk stratification and determine the clinical strategy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nomograms / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nomograms / Precursor Cell Lymphoblastic Leukemia-Lymphoma Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: China